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Abstract: Schizophrenia is a disabling mental illness with a lifetime prevalence of 
0.7% worldwide and significant, often devastating, consequences on social and occupational 
functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic 
response in terms of psychotic symptoms is common and affects up to one-third of people with 
schizophrenia. Negative symptoms are generally less amenable to treatment. Because of the 
consequences of inadequate symptom control, effective treatment strategies are required for 
people with treatment-resistant schizophrenia. Clozapine has been shown to be more effective 
than other antipsychotics in treatment-resistant populations in several studies; however, the 
occurrence of adverse effects, some of which are potentially life-threatening, are important 
limitations. In addition to those who are intolerant to clozapine, only 30% to 50% experience 
clinically significant symptom improvement. This review describes the recent evidence for 
treatment strategies for people not responding to nonclozapine antipsychotic agents and people 
not responding or only partially responding to clozapine.
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Introduction
Schizophrenia is a disabling mental illness with a lifetime prevalence of 
0.7% worldwide.1 Typically beginning in early adolescence, outcomes for patients 
are variable but the course of illness is chronic, often marked with periods of relapse 
despite treatment. Schizophrenia has a significant and often devastating impact on 
social and occupational functioning for patients, often due to residual negative 
symptoms and cognitive deficits.2 This may manifest as the decreased likelihood of 
living independently, being in an intimate relationship, achieving formal education, 
or being in paid employment.3–6 A range of antipsychotic medications is available, 
including first-generation antipsychotics (FGAs) and second-generation 
  antipsychotics (SGAs).7,8 However, suboptimal therapeutic response in terms of 
psychotic symptoms is common and affects up to one-third of people.9 Negative 
symptoms may be classified as primary (part of the disease process itself ) or second-
ary (to factors such as depression, drug-induced akinesia, or a suspicious 
withdrawal)10 and are generally less amenable to treatment.11,12 Antipsychotic agents 
have no demonstrable efficacy for primary enduring or “deficit” negative symptoms.13 
Improvements in this symptom domain are largely a consequence of a reduction in 
positive symptoms.14,15 While antipsychotic agents improve attention in people with 
schizophrenia,16,17 the effects observed for other cognitive impairments are incon-
sistent18 and may include worsening.19,20 The net impact of an antipsychotic agent Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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on cognitive function is determined by the beneficial effect 
on attention and adverse effects related to anticholinergic 
activity and extrapyramidal side effects (EPSE).21 
  Furthermore, it has been postulated that a practice effect 
may account for beneficial effects observed.22 There are no 
apparent consistent differences between antipsychotic 
agents with respect to their effect on cognition.23–25 Because 
of the consequences of inadequate symptom control, effec-
tive treatment strategies are required for people with 
treatment-resistant schizophrenia (TRS).
Several definitions of treatment-resistant schizophrenia 
exist and vary in their specificity. The criteria employed by 
Kane et al to define treatment-resistant (or treatment- 
refractory) schizophrenia in the pivotal trial comparing 
clozapine to chlorpromazine is used frequently in clinical 
trials and audit settings.26,27 Kane et al classified participants 
as treatment-resistant if: improvement had not been demon-
strated after 3 periods of treatment with antipsychotics (from 
2 or more different chemical classes) in the previous 5 years 
equivalent to 1000 mg/day of chlorpromazine (CPZ) for 
6 weeks and participants had had no episodes of good func-
tioning in the previous 5 years, Brief Psychiatric Rating Scale 
(BPRS) total score $ 45, Clinical Global Impressions (CGI) 
score $ 4, and score $ 4 on 2 or 4 positive symptoms items.26 
Conley and Kelly presented a modified version of these 
criteria to reflect clinical practice patterns and a better under-
standing of optimal dosing: 2 antipsychotic trials (400–600 mg 
CPZ equivalents per day) for 4 to 6 weeks with no clinical 
improvement, no period of good social or occupational 
functioning for .5 years, BPRS total score . 45, and a score 
of .4 on 2 of 4 positive items.28
Clozapine has been shown to be more effective than other 
antipsychotics in treatment-resistant populations in several 
studies; however, the occurrence of adverse effects, some of 
which are potentially life-threatening, are important   limitations. 
In addition to those who are intolerant to clozapine, only 
30% to 50% experience clinically significant symptom 
improvement.29,30 This has prompted unlicensed prescribing 
and antipsychotic combination strategies (with or without 
clozapine) for which there is the potential for increased side 
effects and little robust evidence to support this practice.
This review will summarize key studies and recent evi-
dence for treatment strategies for people not responding to 
nonclozapine antipsychotic agents and people not responding 
or only partially responding to clozapine. The literature 
reviewed was identified by a systematic search of Ovid 
Medline & Medline In-Process, Embase (combined file 
1947 to present), Cochrane Central Register of Controlled 
Trials (CENTRAL/CCTR), and PsycINFO, supplemented 
by hand searches of reference lists. The evidence is pre-
sented in 3   sections: clozapine monotherapy versus other 
antipsychotics, clozapine augmentation strategies, and 
options for clozapine-intolerant or clozapine-resistant people. 
The first section is divided into 2 parts comparing clozapine 
monotherapy to FGAs and SGAs; each part is stratified by 
the level of evidence presented. The clozapine augmentation 
section is first stratified by level of evidence (meta-analysis 
or randomized controlled trial) then by specific treatment 
strategy. The structure of this section reflects the relative 
availablity of evidence for the treatment combinations 
  considered. The third section, treatment options for those 
who are intolerant or resistant to clozapine, discusses alterna-
tive antipsychotic monotherapy and nonpharmacological 
treatments.
Clozapine monotherapy
The World Psychiatric Association Section on Pharmaco-
psychiatry utilized data from approximately 1600 random-
ized controlled trials of 51 FGAs and 11 SGAs in the 
treatment of schizophrenia.31 Modest benefits were observed 
for the use of SGAs compared to FGAs for negative, cogni-
tive, and depressive symptoms, and with a lower risk of 
tardive   dyskinesia. These benefits were mainly attributed to 
the ability of SGAs to provide improvement in positive 
symptoms, equivalent to that of FGAs, with a lower risk of 
EPSE. There were no consistent differences between SGAs 
in terms of efficacy with the exception of clozapine, which 
was found to be more efficacious than other antipsychotics 
in people who had not responded to 1 or more other antip-
sychotics. Adequate trials of adequate doses of FGAs and 
SGAs were found to be key variables in optimizing effective-
ness of antipsychotic agents. Substantial individual vari-
ability was observed in treatment response and adverse 
effects. SGAs offer the advantage of fewer acute extrapyra-
midal symptoms and less likelihood of tardive dyskinesia 
but produce greater metabolic side effects. Meta-analyses 
published subsequent to this summary statement and key 
trials on the use of   clozapine are presented below.
Clozapine monotherapy versus FGA agents
Meta-analyses
Leucht et al compared treatment outcomes between SGAs and 
FGAs in people with schizophrenia in general in a meta-
analysis of 150 double-blind randomized studies including 
21,533 participants.32 The meta-analysis by Essali et al also 
compared treatment outcomes between those taking FGAs Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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versus SGAs and was largely based on the same data.33 
Four SGA agents emerged as superior to FGA agents: 
  clozapine, amisulpride, olanzapine, and risperidone.32 The 
majority of studies (121) were of 12 weeks’ duration, 17 were 
of 6 months’ duration, and 12 were longer than 12 months. 
It has been postulated that EPSE associated with FGAs may 
mimic the symptoms of schizophrenia and in early randomized 
controlled trials (RCTs) falsely suggested that SGAs are 
superior.34–36 In order to avoid this potential problem, only 
participants taking #12 mg/day haloperidol (or #600 mg/day 
chlorpromazine equivalents for low-  potency FGAs) were 
included in this meta-analysis. Positive and Negative Symp-
tom Scale (PANSS) and BPRS scores were used to assess 
overall efficacy and specific symptoms domains all of which 
were found to be more amenable to treatment with clozapine, 
olanzapine, amisulpride, or risperidone versus FGAs.
Treatment with clozapine  produced medium effect sizes: 
overall symptoms −0.52 (95% confidence intervals [CI]: −0.75 
to −0.29, P , 0.0001), positive symptoms −0.36 (CI:−0.56 to 
−0.16, P , 0.0001), negative symptoms −0.27 (CI: −0.42 to 
−0.13, P , 0.0001), depression −0.51 (CI: −0.87 to −0.14, 
P = 0.006). Amisulpride and olanzapine produced similar 
improvements compared to FGAs: overall symptoms −0.31 
(CI: −0.44 to −0.19, P , 0.0001) and −0.28 (CI: −0.38 to −0.18, 
P , 0.0001), respectively, positive symptoms −0.22 (CI: −0.37 
to −0.06, P = 0.005) and −0.15 (CI: −0.21 to −0.09, P , 0.0001), 
negative symptoms −0.27 (CI: −0.40 to −0.14, P , 0.0001) 
and −0.32 (CI: −0.47 to −0.16, P , 0.0001), depression −0.37 
(CI: −0.51 to −0.24, P , 0.0001) and −0.27 (CI: −0.35 to −0.19, 
P , 0.0001). The effect sizes associated with risperidone were 
small and the improvement observed on the depression subscale 
was not significant: overall symptoms −0.13 (CI: −0.22 to 0.05, 
P = 0.002), positive symptoms −0.13 (CI: −0.20 to 
−0.05, P = 0.001), negative symptoms −0.13 (CI: −0.21 to 
−0.06, P , 0.0001), depression −0.10 (CI: −0.23 to 0.03, 
P = 0.145). Industry sponsorship, comparator dose, and pro-
phylactic EPSE medication were assessed as moderator vari-
ables but did not yield any consistent effects. Leucht et al 
concluded that this reflects the fact that FGAs and SGAs are 
heterogeneous classes of compounds and argued that such 
categorization can lead to improper generalization and 
confusion.32
Randomized controlled trials
Meltzer et al investigated the use of clozapine versus FGAs 
in treatment responsive participants during a 24-month study.37 
Significant improvements in psychopathology, quality of 
life and global functioning were observed in both the 
clozapine (n = 40) and FGA group (n = 45) after taking a 
range of antipsychotic agents; most commonly haloperidol 
but also perphenazine, fluphenazine, loxapine, thioridazine, 
thiothixene, molindone, and amoxapine. While a similar 
improvement in psychopathology was observed, signifi-
cantly more relapse/rehospitalization drop-outs occurred in 
those taking FGAs (19 relapse related hospitalizations 
in 10 participants versus 11 relapse related hospitalizations 
in 4 participants treated with clozapine). There were no 
differences in the occurrence of EPSEs between clozapine 
and the FGA groups; however, clozapine was associated 
with more weight gain.
In a 12-week double-blind trial, Krakowski et al randomly 
assigned participants with schizophrenia or schizoaffective 
disorder to receive clozapine (n = 33), olanzapine (n = 34), 
or haloperidol (n = 33).38 People with a history of nonresponse 
or intolerance to any of the 3 study medications were 
excluded. Aggression was assessed using the Modified Overt 
Aggression Scale (MOAS) and a cognitive task battery tested 
general executive function, visuospatial ability, psychomotor 
function, and visual and verbal memory. In the general cogni-
tive index (GCI) no significant improvement was observed 
in the haloperidol or clozapine group while clozapine was the 
most efficient medication in reducing aggression. An impor-
tant limitation was the concomitant, prophylactic use of 
benztropine 4 mg/day for EPSE in the group taking haloperi-
dol, which may increase anticholinergic cognitive   impairment. 
Participants taking haloperidol showed no increase in body 
weight, blood lipids, or glucose.39
Clozapine monotherapy versus  
other SGA agents
Meta-analyses
The Cochrane Schizophrenia Group performed a meta-
analysis in order to compare several commonly used SGA 
agents in terms of efficacy and tolerability in people with 
schizophrenia or schizophrenia-like psychoses.40 The pri-
mary outcome measure selected to assess this was change in 
total PANSS score, with positive and negative subscores as 
secondary outcomes. Outcomes were reported using 
weighted mean difference (WMD) in terms of PANSS scores 
and the dropout rate due to poor efficacy was included as a 
further outcome measure. Seventy-eight randomized, double-
blind studies were included for analysis of which 28 included 
treatment with clozapine.
The results relating to clozapine were different to those 
anticipated based on previous reports. No significant differ-
ences were found when comparing the total PANSS scores Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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between clozapine and olanzapine (N = 619), quetiapine 
(N = 232), risperidone (N = 466), or ziprasidone (N = 146); 
however, clozapine was found to be significantly more effica-
cious than zotepine (N = 59, WMD = −6.0, P = 0.002). 
The results for a decrease in positive symptoms reflected those 
found for overall symptoms while quetiapine was found to be 
more efficacious than clozapine on the negative symptom sub-
score (N = 142, WMD = 2.2, P , 0.001). Clozapine was 
favored over risperidone when comparing dropout rates due 
to poor efficacy (N = 627, relative risk [RR] = 0.40 95% con-
fidence interval [CI] 0.23–0.70, P = 0.001). These unexpected 
results may be due to the low or very low doses of clozapine 
that were used in many of the studies included; several had an 
upper limit of 400 mg/day and 5 used dosages under 
210 mg/day. In the pivotal studies that established clozapine’s 
effectiveness, the average daily dose of clozapine was 
600 mg/day and 523 mg/day.26,41   Furthermore the participants 
included in these trials may not have been as treatment refrac-
tory as those in other studies demonstrating clozapine’s supe-
riority over other SGA agents.
Substantial concerns about the side effects induced by 
SGA agents such as weight gain and metabolic syndrome 
may offset modest differences in their effectiveness. In a 
meta-analysis of head-to-head comparisons of the metabolic 
effects between SGA agents, Rummel-Kluge et al assessed 
weight gain and changes in cholesterol and glucose over 
48 studies.42 There were 3 main clusters in terms of these 
outcomes: olanzapine and clozapine produced the greatest 
elevation in weight, cholesterol and glucose (with no signifi-
cant difference between the 2 agents) followed by quetiapine, 
risperidone, and sertindole with intermediate elevations. 
Aripiprazole and amisulpride showed lower elevations and 
ziprasidone the lowest. The authors noted that the dose of 
antipsychotic influenced some of the results in meta- 
regressions; for example a high dose of olanzapine tended 
to produce a greater difference in the outcome measure in 
favor of the comparator drug. Another important caveat is 
that data on prior antipsychotic treatment for the participants 
in the selected studies were not available for analysis.
Randomized controlled trials
Phase II of the Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE) recruited 99 participants who discon-
tinued treatment with olanzapine, quetiapine, risperidone, 
or ziprasidone in phase I or IB of the trial primarily due to 
inadequate efficacy.43 Participants were randomized to 
blinded treatment with another newer SGA not previously 
received in the trial (olanzapine n = 19, quetiapine n = 15, or 
risperidone n = 16) or open label treatment with clozapine 
(n = 49). At 3-month assessments, participants treated with 
clozapine experienced a greater reduction in PANSS total 
score (mean = −11.7, standard error [SE] = 3.2) than partici-
pants treated with quetiapine (mean = 2.5, SE = 4.8) or ris-
peridone (mean = 4.1, SE = 1.9) but not olanzapine 
(mean = −3.2, SE = 2.3). Clozapine was significantly better 
only than quetiapine on the PANSS general psychopathology 
subscale (mean = −4.7, SE = 1.5 versus mean = 2.3, SE = 2.5, 
P = 0.006). Time to discontinuation for any reason was sig-
nificantly longer for clozapine (median = 10.5 months) than 
for risperidone (2.8 months) or quetiapine (median = 3.3 months) 
but not olanzapine (median = 2.7 months). Time to 
  discontinuation is subject to bias in this phase of the study. 
Because treatment allocation was known to both clinicians 
and participants there may have been reluctance to discon-
tinue clozapine, it being widely considered the best option 
for treatment-resistant schizophrenia. The data from this study 
support the conclusion that, for participants who prospectively 
failed to improve with an SGA, treatment with clozapine was 
more effective than switching to another SGA.
Phase III of CATIE allowed 270 participants who had 
discontinued antipsychotics in Phases I and II to select 
treatment from 9 antipsychotic regimens with the help of their 
study doctor.7 Approximately equal numbers of participants 
chose 7 of the 9 antipsychotics including clozapine 
(33–41 participants each agent). The study used a double-
blind design with the exception of those treated with clozap-
ine, which was open label. The blinding of treatment with 
clozapine would have required additional monitoring of all 
treatment groups for clozapine specific safety issues, and in 
doing so may have affected the ecological validity of the other 
agents. All of the commonly used treatments were associated 
with substantial symptom improvement at 3 months 
and 6 months, with the exception of aripiprazole at 3 months 
and ziprasidone and quetiapine at 6 months. A total of 106 par-
ticipants discontinued treatment; there were no significant 
differences in the proportions of participants who discontin-
ued the commonly selected medicines (range 33%–46%). 
However, discontinuation due to lack of efficacy was lower 
for clozapine (5%), risperidone, quetiapine, and ziprasidone 
(0%–5%) than olanzapine, aripiprazole, and combination 
treatment (13%–18%). Adverse effects were problematic in 
the group taking clozapine; the rates of adverse events 
classified as moderate or severe were highest for   clozapine 
(35%), quetiapine (45%), and combination antipsychotic treat-Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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ment (30%). Clinically significant weight gain of at least 7% 
was common with clozapine (32%), combination antipsychotic 
treatment (39%), and olanzapine (23%). All other SGA agents 
were associated with weight loss, in particular aripiprazole 
and ziprasidone, which produced the greatest monthly weight 
loss of 0.64 kg and 0.59 kg,   respectively; clozapine produced 
a gain of 0.59 kg/month.
Krakowski et al reported that olanzapine outperformed 
clozapine in terms of neurocognitive function in a study of 
100 physically aggressive inpatients with schizophrenia or 
schizoaffective disorder.38 For metabolic parameters, partici-
pants taking olanzapine gained the most weight compared with 
clozapine or haloperidol, but clozapine was associated with 
the greatest increases in serum cholesterol, triglycerides and 
glucose.39 In the GCI olanzapine was found to be superior 
(improvement was approximately 0.5 standard deviations 
[SD]) to both clozapine and haloperidol; this was also associ-
ated with a decrease in aggression which was assessed using 
the MOAS. Rather than concluding that olanzapine has a 
procognitive effect it is perhaps more likely that olanzapine 
has less cognitive liability; clozapine has strong intrinsic anti-
cholinergic activity compared with olanzapine.44 Nonetheless, 
treatment with clozapine markedly reduced aggression, sug-
gesting that the antiaggressive effects of olanzapine may be 
mediated by different neuronal pathways.
It has been suggested that a decrease in serum choles-
terol may result in aggression due to the subsequent 
decrease in brain serotonergic activity, given that choles-
terol determines the availability of serotonin receptors and 
transporters.45 In a post-hoc analysis of the relationship 
between serum cholesterol levels and aggression in these 
groups, Krakowski and Czobor found a negative correlation 
at baseline.46 Based on changes in total cholesterol (TC) 
over the 12-week study period, the investigators used a 
Glimmix regression model to predict changes in aggression 
(Krakowski, pers comm). For those taking haloperidol it 
was predicted that a 141.9% increase in physical aggression 
was associated with a decrease of 1 SD unit in TC levels. 
Participants whose cholesterol increased by 1 SD in the 
clozapine group were predicted to be 67.6% (P , 0.001) 
less physically aggressive than those whose cholesterol did 
not change. It was then postulated that the antiaggressive 
effects of clozapine may have been further enhanced by an 
increase in cholesterol.
The UK Cost Utility of the Latest Antipsychotic Drugs 
in Schizophrenia Study 2 (CUtLASS 2) included 136 people 
with schizophrenia and related disorders whose medication 
was being changed due to suboptimal response to 2 or more 
previous antipsychotic agents.47 Participants were randomly 
allocated to receive clozapine or another SGA agent (risperi-
done, olanzapine, quetiapine, or amisulpride) selected by the 
treating clinician. The trial was rater-blind and outcome 
assessments were carried out for 87% of the participants at 
12, 26, and 52 weeks following randomization. No significant 
advantage was observed for those taking clozapine compared 
with other SGA agents in the Quality of Life score 
(3.36 points, 95% CI 0.46–7.71); however, a significant 
improvement was seen in the PANSS total score (−4.93, 95% 
CI −8.82 to −1.05). At 12 weeks the group taking clozapine 
reported that their mental health was significantly better than 
those taking other SGA agents. There were no significant 
differences between the treatment groups in the rate of 
adverse effects including weight gain.
Suicide has been identified as the leading cause of pre-
mature death among people with schizophrenia.48 The 
International Suicide Prevention Trial (InterSePT) assessed 
the risk for suicidal behavior in 980 participants with 
schizophrenia or schizoaffective disorder treated with clo-
zapine compared to olanzapine over a 2-year period.49 Par-
ticipants in this study, 26.8% of whom were refractory to 
previous treatment, were considered at high risk for suicide 
because of previous attempts or the presence of suicidal 
ideation. The study was conducted as an open-label trial 
with masked ratings. Suicidal behavior, defined as suicide 
attempts and hospitalizations to prevent suicide, was 
observed less frequently in those taking clozapine versus 
olanzapine (hazard ratio [HR] 0.76, 95% CI 0.58–0.97). 
Worsening on the CGI-Suicide Severity or implicit worsen-
ing as demonstrated by occurrence of suicidal behavior was 
also less frequent in those taking clozapine (HR 0.78, 95% 
CI 0.61–0.99). Fewer clozapine treated participants 
attempted suicide, required hospitalizations or rescue inter-
ventions to prevent suicide (34 versus 55, P = 0.03, 82 
versus 107, P = 0.05 and 118 versus 155, P = 0.01, respec-
tively). The need for concomitant antidepressants or anxi-
olytics/soporifics was also less frequent in those taking 
clozapine compared with olanzapine (221 versus 258, 
P = 0.01 and 301 versus 331, P = 0.03). Although the num-
ber of completed suicides was greater in the clozapine 
group (5 clozapine-treated participants   versus 3 olanzapine-
treated participants, P = 0.73), this was not significant and 
the study was not powered to evaluate this as an endpoint. 
It was recognized by the investigators at the outset that the 
study would need to include 20,000 participants to detect Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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a decreased relative risk for suicide deaths with clozapine 
therapy by 20%.
In a randomized double-blind trial, Harvey et al compared 
the cognitive performance of 130 people with schizophrenia 
after 12 weeks of treatment with clozapine (n = 69) or 
ziprasidone (n = 61).50 All participants were either resistant 
or intolerant to previous antipsychotic treatment. Clozapine-
treated participants showed improvement on the Rey Audi-
tory Verbal Learning Test (RAVLT; episodic memory) and 
the Stroop interference test (executive function) but not the 
Trail-Making Test (TMT; parts A and B; processing speed) 
compared with those taking ziprasidone. None of the indi-
vidual items were observed to improve at 12 weeks between 
the treatment groups; however the composite score improved 
significantly in those taking ziprasidone compared with 
clozapine (effect size D = 0.54, P = 0.029). One possible 
explanation for these results is that clozapine may interfere 
with the performance benefits of practice effects. Although 
it appears that ziprasidone is superior in reducing cognitive 
deficits in this short-term trial, clinical efficacy in terms of 
symptom control was not reported.
Davies et al compared clozapine to available SGA agents 
in a UK multi-center, rater-blind RCT in people with 
  psychosis eligible for clozapine to assess cost-  effectiveness.51 
Over a 1-year period, it was found that clozapine was associ-
ated with higher quality-adjusted life years (QALYs) than 
other SGA agents, but at an additional cost. The probability 
that clozapine is cost-effective reached 50% if in order to 
gain 1 QALY the decision-makers were willing to pay 
£33,000. In other words, if the decision-makers were willing 
to pay less than £33,000 to gain 1 QALY, other SGA agents 
may be more cost-  effective than clozapine. However, this 
trial was conducted with a relatively small number of 
  participants (n = 67 clozapine; n = 69 other SGA agents) and 
post-hoc calculations indicated that the power to detect sig-
nificant differences in net money benefit was low (50% if 
important differences in costs and QALYs were defined as 
£1600 and one-twentieth of a QALY,   respectively). Further-
more, it may not be possible to extrapolate the results to 
longer-term clozapine treatment or to a population of primar-
ily treatment-resistant people. The authors also noted that 
clozapine may be more cost-effective if fewer participants 
had clozapine initiated as an inpatient than in this RCT.
The present review found 2 RCTs comparing clozapine 
monotherapy with treatment with high-dose olanzapine52,53 
and a further study examining treatment with ziprasidone 
with treatment-resistant participants.54 These studies will be 
discussed in detail below.
Clozapine augmentation
Despite proven efficacy in people with schizophrenia show-
ing sub-optimal response to other antipsychotics, only 
30% to 50% of people will experience clinically significant 
symptom improvement with clozapine treatment.29,30 
One-third to two-thirds of people will continue to experience 
positive symptoms with adequate doses of clozapine or will 
be unable to reach adequate levels due to side effects that 
prevent further dose increases.30 Antipsychotic monotherapy 
is preferred over augmentation according to schizophrenia 
treatment algorithms; for people who do not respond to 
first-line antipsychotics, clozapine is recommended. There-
fore clozapine augmentation strategies should be imple-
mented only for those who experience insufficient response 
to clozapine monotherapy. An operational definition of 
nonresponse to clozapine or ‘ultraresistant’ schizophrenia 
is: BPRS improvement of ,20% despite a trial with clozap-
ine for $8 weeks and plasma levels .350 µg/L, no stable 
period of good social and/or occupational functioning 
for $5 years, Global Assessment of Functioning (GAF) # 
40, BPRS total score $ 45, CGI score $ 4, and a score 
of $4 on 2 of 4 positive symptom items.55
Meta-analyses
Augmentation with other antipsychotics
The present review found 4 meta-analyses on the augmenta-
tion of clozapine treatment with another antipsychotic for 
people  with  an  inadequate  response  to  clozapine 
monotherapy.56–59 These meta-analyses were based on essen-
tially the same data, the largest of which was conducted by 
Barbui et al and arrived at similar conclusions with the excep-
tion of Correll et al.56,58
Barbui et al selected 21 studies to determine the efficacy 
of a second antipsychotic in combination with clozapine.56 
The number of trials evaluating each augmentation agent 
was chlorpromazine n = 1, pipothiazine n = 2, amisulpride 
n = 1, sulpiride n = 7, and the remainder used risperidone 
(n = 10). The mean length of follow up was 13.8 weeks 
(SD = 19.6) and the trials were divided into either short-term 
studies of less than 10 weeks’ duration or long-term studies. 
Clozapine combination strategies were favored in 14 open 
(nonblind), randomized studies in terms of effect size or 
standardized mean difference (SMD) from various outcome 
scales (SMD = −0.80, 95% CI −1.14 to −0.46). However, 
this trend was not apparent in 6 of the RCTs (SMD = −0.12, 
95% CI −0.57 to 0.32). Subgroup analysis by trial duration 
revealed a similar trend: the open studies favored clozapine 
combinations in both long- and short-term trials, the blinded Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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studies showed no advantage for clozapine combinations of 
either duration.
Correll et al found antipsychotic combinations in general 
to be advantageous over monotherapy in a meta-analysis of 
19 studies (1229 participants) in terms of all cause discon-
tinuation (n = 1052, RR 0.65, 95% CI 0.54–0.78) and less 
study-specific inefficacy (n = 1202, RR 0.76, 95% CI 
0.63–0.90).58 The mean trial duration was 12.1 weeks (range 
4–52 weeks). The most commonly used antipsychotic was 
clozapine, though a variety of antipsychotic combinations 
were used. In terms of lack of efficacy as defined by each 
study, co-  treatment including clozapine was superior to 
antipsychotic monotherapy (n = 764, RR 0.75, 95% CI 
0.61–0.93); however, the specific augmenting agents were 
not presented separately within the results. Meaningful 
results regarding specific psychopathology and adverse 
events could not be calculated due to insufficient data. 
  Sensitivity analyses identified 5 efficacy moderators: clozap-
ine combinations, concurrent polypharmacy initiation,   
Chinese trials, trial duration .10 weeks, and SGA–FGA 
combinations. Meta-  regression of variables from sensitivity 
analyses identified 3 significant moderators associated with 
superior efficacy of antipsychotic combinations: similar 
doses in the mono- and polytherapy arm (P = 0.006, 
coeff = 0.48), SGA + FGA combinations (P = 0.027, 
coeff = 0.39) and concurrent polypharmacy initiation   
(P = 0.050, coeff = 0.35). The findings of this study differ 
from those of other meta-analyses of antipsychotic combina-
tion treatment and it is important to note that the positive 
results for antipsychotic combinations observed were primar-
ily from Chinese studies not included in the other meta-
analyses. A high degree of heterogeneity within the database 
and possible publication bias further obscured the signifi-
cance of these findings.
Overall, it appears that the evidence considered for 
  clozapine augmentation with another antipsychotic in these 
meta-analyses is weak and observed benefits are moderate at 
best. One consideration to take into account is that these 
reviews combined results of all antipsychotic augmentation 
irrespective of mechanism of action.
Augmentation with anticonvulsants
Dysfunctional glutamatergic neurotransmission is postulated 
to be an important component underlying the   pathophysiology 
of schizophrenia.60 Lamotrigine is an anticonvulsant drug 
that inhibits excessive glutamate release in the brain by 
antagonism of sodium channels and increases gamma-zyric 
acid (GABA) release. It has been used as an augmenting 
agent on this basis.61,62 Tiihonen et al examined the 
advantages of combining clozapine with lamotrigine in 5 
randomized placebo-controlled trials (161 participants) of 
10 to 24 weeks’ duration.63 On the primary outcome measure 
the total score for symptoms of psychosis, the clozapine–
lamotrigine combination was superior to the clozapine–
placebo combination (SMD 0.57, 95% CI 0.25–0.89; 
number needed to treat [NNT] 4, 95% CI 3–6). The second-
ary outcome measures also favored this combination (SMD 
0.34, 95% CI 0.02–0.65 for decreasing positive symptoms 
and SMD 0.43, 95% CI 0.11–0.75 for improving negative 
  symptoms). The incidence of severe adverse effects or drop-
out rate did not differ between the treatment groups. No 
significant heterogeneity was observed in the meta-analysis. 
Importantly, this is the first evidence to date of efficacy for 
any pharmacological treatment in clozapine-resistant schizo-
phrenia and it is noted by the authors that similar benefits 
may not be observed with lamotrigine and other antipsy-
chotic agents apart from clozapine. The effect size for total 
score for symptoms of psychosis was 0.57, suggesting ben-
eficial effects for general symptoms which are known to be 
robust predictors of functional outcomes; however, scores 
were not available for all studies.64
Augmentation with NMDA agonists
Like anticonvulsants, the use of N-methyl-D-aspartate 
(NMDA) -enhancing agents is predicated on the glutamate 
hypothesis of schizophrenia, specifically NMDA receptor 
hypofunction. Antagonists of NMDA receptors such as 
phencyclidine and ketamine produce psychotic symptoms 
and neurocognitive deficits in human subjects and exacerbate 
psychotic symptoms in people with schizophrenia.65–67   Agonists 
at the obligatory NMDA-  glycine binding site are glycine, 
D-serine, and D-alanine and the partial agonist D-cycloser-
ine, as opposed to agonists at the NMDA recognition site, 
which are excitotoxic. These agents, in addition to sarcosine 
which increases the availability of glycine in the synapse 
by inhibiting the glycine transporter-1 (GlyT-1), have been 
investigated as potential therapeutic agents for   schizophrenia. 
Tsai and Lin performed a meta-analysis of 26 double-blind, 
placebo-controlled trials in approximately 800 people taking 
an NMDA agonist in addition to stable doses of antipsy-
chotic medication for at least 4 weeks.68 Almost all studies 
used the PANSS to assess symptom severity. The pooled 
effect size of clinical efficacy of NMDA agonist augmentation 
compared with placebo for total psychopathology was 0.40 
(95% CI 0.22–0.58) and significant improvement was noted 
for depressive, negative, cognitive, positive, and general Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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symptoms. Treatment with glycine, D-  serine, and sarcosine 
was associated with improvement in multiple symptom 
domains while D-cycloserine was not. The concomitant 
antipsychotic used appeared to affect the efficacy of the 
NMDA-enhancing agent; those treated with risperidone or 
olanzapine improved, but those treated with clozapine did 
not. Gastrointestinal (GI) upset and nausea were noted more 
often in some glycine trials while other side effects were 
equivalent for NMDA-enhancing agents and placebo. 
Despite a moderate effect size, the efficacy of these agents 
may have been overstated due to limitations within the study. 
For instance, studies were included only if they provided 
“enough data to calculate the effect size” and a test for 
homogeneity revealed that there may have been systematic 
differences among the included studies. Another important 
caveat is that D-cycloserine, D-serine, D-alanine, and sar-
cosine are protected by US patents for which the study 
author is a patent holder.
Randomized controlled trials
Augmentation with anticonvulsants
Topiramate is a GABAergic anticonvulsant drug indicated 
as add-on pharmacotherapy for adults and children with 
primary generalized tonic–clonic and partial-onset seizures. 
It has been used for people with schizophrenia to correct a 
postulated glutamate deregulation due to NMDA receptor 
hypofunction. Topiramate is thought to potentiate inhibitory 
GABAergic transmission (probably through a nonbenzodi-
azepine mechanism) and inhibit the activity of kainite on the 
AMPA/kainate receptor subtype.69–73
Two studies have examined the use of topiramate as an 
adjunct to treatment to clozapine with contrasting results. 
Afshar et al conducted a double-blind trial over 8 weeks 
with 32 people receiving clozapine treatment for at least 
2 months.74 Participants were randomized to receive up to 
300 mg/day of topiramate (n = 16) or placebo in addition to 
clozapine (n = 16). Total PANSS scores at baseline were 
similar between the groups, indicating a suboptimal response 
to clozapine monotherapy (topiramate group 96.87 ± 21.98; 
placebo group 101.87 ± 23.05, P = 0.53). Clinically signifi-
cant improvement was defined as a .20% decrease in   
total PANSS score and was observed in 8 participants   
(50%) in the topiramate group and 2 in the placebo group 
(12.5%; P , 0.05). The differences in the groups’ total 
PANSS mean scores were reported at both 3 and 8 weeks 
and favored topiramate augmentation: −11.18 ± 8.72 
  versus −1.56 ± 9.23, P = 0.005 and −20.00 ± 11.96 
  versus −1.31 ± 11.13, P , 0.001,   respectively. At 8 weeks 
a number of side effects were more prevalent in the topira-
mate group such as hypersalivation (75.0% versus 34.7%, 
P # 0.05) (although this was reported to be present in some 
participants prior to the study), psychomotor retardation 
(50.0% versus 6.2%, P # 0.01), and paresthesia (37.5% 
versus 6.2%, P # 0.05). Weight loss was also reported more 
commonly in the topiramate group (37.5% versus 6.2%, 
P # 0.05). However, the authors reported that there were 
no differences observed in body mass index (BMI) between 
the groups or within each group over the trial period. None 
of the participants dropped out of the trial due to drug- 
induced adverse effects. While the results of this small trial 
appear to favor topiramate augmentation, the follow-up 
period is relatively short.   Furthermore, the investigators did 
not assess cognitive impairment, a well-documented, dose-
dependent adverse effect of topiramate that is particularly 
relevant to people with schizophrenia.75–78
The double-blind RCT by Muscatello et al79 was a meth-
odologically robust 24-week study that failed to replicate the 
benefits of topiramate add-on pharmacotherapy reported by 
Afshar et al.74 People receiving clozapine for at least 1 year, 
at a stable dose for at least 1 month, with a BPRS score 
of $25 were eligible to participate. The clozapine dose 
remained unchanged throughout the study and participants 
noncompliant with all 10 study visits were excluded. No last 
observations were carried forward since this introduces 
assumptions which can under- or overestimate the effects of 
treatment.80 Participants did not receive any antidepressants 
or anticonvulsants for a period of 2 months prior to the study. 
A maximum dose of 200 mg/day topiramate was added to 
clozapine treatment (n = 19; placebo n = 24). No significant 
improvement in positive, negative, affective, or overall 
symptomatology from baseline to week 24 was observed. 
In the topiramate group a significant reduction was observed 
using the scale for the assessment of positive symptoms 
(SAPS) subscale for bizarre behavior (including clothing and 
appearance, aggressive behavior, stereotyped behavior and 
social, and sexual behavior).81 No significant effects on 
cognitive functioning were observed as measured by the 
Stroop test, verbal fluency, and the Wisconsin Card Sorting 
Test (WCST). No serious adverse events were reported; 
however, adjunctive topiramate was more frequently 
associated with asthenia, sedation, and paresthesia while 
constipation and hypersalivation were reported in the placebo 
group. There was no significant change in body weight from 
baseline to the end of the trial for the topiramate group.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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It is possible that this trial did not prove topiramate to be 
as useful for clinical symptomatology as the previous study 
because a lower dose of topiramate was used (200 mg/day 
versus 300 mg/day). Yet this dose was chosen based on find-
ings by Deutsch et al82 in order to avoid cognitive impairment 
which was not assessed by Afshar et al.74 Furthermore, the 
very small topiramate group (n = 19) means that only a large 
change in SAPS or WCST would produce a statistically 
significant difference. From these studies it appears that at 
doses low enough to preserve cognitive function, topiramate 
is of little benefit for clinical symptoms.
Augmentation with cognitive enhancing agents
Memantine is a weak, nonselective NMDA receptor antago-
nist approved for use in the treatment of moderate to severe 
Alzheimer’s disease. De Lucena et al studied the effects of 
20 mg/day memantine combined with clozapine treatment 
for negative symptoms over 12 weeks.83 This double-blind 
trial was small (memantine n = 10, placebo n = 11) and 
consisted of those taking clozapine for at least 10 years for 
TRS. Significant improvements were seen at week 12 in the 
active treatment group for the total BPRS score (19.00 versus 
43.18, P = 0.001) and on the positive and negative symptom 
subscales (4.10 versus 9.18, P = 0.007 and 6.10 versus 13.55, 
P = 0.001). Those taking memantine also showed an 
6.12-point (95% CI 4.45–7.79) increase in mean score on 
the Mini-Mental State Examination (MMSE), although this 
is not the most sensitive measure of cognitive functioning.84 
Simpson-Angus Scale (SAS) score and body weight were 
not significantly different between the groups. Based on 
results from animal studies, it has been postulated that 
memantine may improve cognitive function by upregulating 
the expression of brain-derived neurotrophic factor (BDNF) 
in humans.85 In this study, however, de Lucena did not detect 
an association between memantine treatment and increased 
serum BDNF levels, which have been highly correlated with 
cerebrospinal fluid BDNF levels.86 This may be due to the 
small sample size or clozapine treatment prior to randomiza-
tion, which may also have increased serum BDNF levels.87
From this small trial, it appears that memantine may have 
beneficial effects in treatment-resistant people taking clo-
zapine in particular; previous studies have not reported   
this effect in people taking atypical antipsychotics apart 
from clozapine.88 Other cognitive enhancing agents such as 
CX516 (an ampakine) and modafinil (a wakefulness- 
promoting agent) have shown less promising results in recent 
randomized controlled trials.89,90 CX516 did not improve 
PANSS scores after 4 weeks of co-administration with 
  clozapine (n = 24), olanzapine (n = 18), or risperidone (n = 9) 
and was associated with fatigue, insomnia, and epigastric 
upset compared with placebo.90 In an 8-week trial, modafinil 
did not worsen psychosis in 35 people taking clozapine 
concurrently but also failed to reduce fatigue, negative 
symptoms, or cognitive deficits.89
Augmentation with aripiprazole
As a partial D2 agonist, aripiprazole’s mechanism of action 
is distinct from that of other antipsychotics. It is a partial 
agonist at 5-HT1A receptors, an agonist at 5-HT2 receptors, 
and has been described as the prototype of a new generation 
of antipsychotic agents, the dopamine-serotonin system 
stabilizers.91 Partial agonism may be a beneficial property by 
allowing optimal neurotransmission, for instance, by acting 
as an antagonist in areas where there is an abundance of 
dopamine causing psychosis while acting as an agonist at 
receptor sites where low dopaminergic tone would produce 
adverse effects such as EPSE or hyperprolactinemia.92 Adverse 
effects associated with this drug such as somnolence, head-
ache, light-headedness, and GI upset may be explained by 
its affinity for several other receptors including D3, D4, 
5-HT2C, 5-HT7, α1, and H1.
Millar et al studied aripiprazole or placebo in combina-
tion with clozapine in suboptimally controlled outpatients 
over a period of 16 weeks.93 Participants in this double-blind, 
randomized study were on a stable dose of clozapine for at 
least 3 months and had gained at least 2.5 kg since starting 
clozapine. At week 16, co-treatment with aripiprazole was 
associated with a significant decrease in mean weight com-
pared with placebo (aripiprazole 2.53 kg, placebo 0.018 kg; 
P , 0.001) and waist circumference (aripiprazole −2.00 cm, 
placebo 0 cm; P , 0.001). Both treatment groups showed 
similar improvement in the GAF. Improvements on the 
Epworth Sleepiness Scale and Fatigue Syndrome Inventory 
were observed in both groups; a significant difference in 
favor of aripiprazole was seen only in week 1.
In an open-label extension of a 16 week double-blind 
placebo controlled trial (reviewed in the meta-analysis by 
Taylor and Smith 2009),59 Fleischhacker et al administered 
aripiprazole (5–15 mg/day) in combination with clozapine 
to all participants.94 For participants previously randomized 
to adjunctive placebo then treated with adjunctive 
  aripiprazole for 12 weeks, the weight loss from the end of 
the double-blind phase was greater (1.74 kg versus adjunc-
tive aripiprazole 0.47 kg). This finding suggests that while Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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the weight loss was maintained in the initial aripiprazole 
group, this effect may plateau after a period of time. Clini-
cally relevant weight loss from baseline was seen in 13% 
of those previously in the placebo group and in 21% of 
those taking aripiprazole for 28 weeks. Differences in 
PANSS scores were not significant between treatment 
groups in either phase of the study. The authors reported 
that symptom improvements were maintained; however, 
only the week 16 PANSS results were reported. Similarly, 
it was reported that participants who switched from placebo 
to aripiprazole at week 12 had reduced TC, low-density 
lipoprotein (LDL) cholesterol, and triglycerides but data 
illustrating this were not supplied.
Phase III of the CATIE study included only 2 participants 
receiving this combination of antipsychotics and therefore it 
was not meaningful to report these separately. However, the 
positive outcomes for weight loss in these randomized con-
trolled trials correspond with findings in CATIE III; treatment 
with aripiprazole was associated with the most monthly 
weight loss (0.64 kg).7 It appears from these trials that the 
addition of aripiprazole counteracts or at least decelerates 
the weight gain as a result of clozapine treatment without 
causing clinical deterioration or improvement.
Options for clozapine-intolerant  
or clozapine-resistant people
Alternative antipsychotics
Two RCTs focused specifically on clozapine versus high 
dose olanzapine in TRS.53,95 Olanzapine is structurally simi-
lar to clozapine but has a different receptor affinity profile, 
being a weaker agonist for α1 and α2 receptors relative to 
its D2, D4, and 5HT2A antagonism. In a 6-month, double-
blind RCT Meltzer et al examined the efficacy and tolerabil-
ity of high-dose olanzapine (target dose 25–45 mg/day; 
mean dose = 34 mg/day; n = 19) versus clozapine (target 
dose 300–900 mg/day; mean dose = 564 mg/day; n = 21) in 
treatment-resistant participants with schizophrenia or 
schizoaffective disorder.53 Between 6 weeks and 6 months 
of treatment, significant and robust improvements were 
observed in both groups using multiple measures of 
  psychopathology. The GAF significantly favored clozapine 
(P , 0.01); however, there were no other significant differ-
ences between each group. While it appears in this small 
trial that high-dose olanzapine was as effective as clozapine, 
significantly more weight gain in the olanzapine group may 
limit its use. At 6 months, the mean increase in BMI for 
those taking olanzapine was 2.2 versus 0.3 for those taking 
clozapine (P = 0.006).
Kumra et al52 concluded in a 12-week controlled 
comparison of 39 adolescents with TRS that clozapine was 
superior to high-dose olanzapine (included in meta-analysis 
by Rummel-Kluge et al).42 In an open-label extension of this 
study, the authors investigated the metabolic side effects of 
these treatments at 24 weeks and the clinical response at 
12 weeks of 10 of the 19 olanzapine-treated participants who 
were switched to clozapine due to nonresponse.95 Clinical 
response was defined as a decrease of at least 30% on the 
BPRS and a CGI-Improvement rating of 1 (very much 
improved) or 2 (much improved). On this basis, 7 of the 10 
participants switched to clozapine were found to respond to 
clozapine. Metabolic side effects were similarly problematic 
in both treatment groups but direct comparisons between the 
groups were difficult to make due to the large proportion of 
participants switched to clozapine. It should also be noted 
that the mean weight of the participants at the beginning of 
this trial corresponded to a mean BMI percentile of 91.3 
(SD = 10.0), which may be accounted for by exposure to 
SGA agents prior to study entry.
With a much higher affinity for 5-HT2 receptors than 
D2 receptors, ziprasidone has one of the highest serotonin/
dopamine binding ratios of the SGA group and a low affin-
ity for H1 and α1 receptors. Sacchetti et al investigated the 
use of ziprasidone compared to clozapine over an 18-week 
period in acutely unwell people (mean PANSS total 
score ∼107) with a history of multiple refractoriness to 
antipsychotics using a double-blind design.54 Decreases in 
the PANSS score were similar in each group;   clozapine −24.5 
(95% CI −29.7 to −19.2) and ziprasidone −25.0 (95% 
CI −30.2 to −19.8). Discontinuation rates due to adverse 
effects were similar however, ziprasidone offered the 
advantage of a more favorable metabolic profile (in terms 
of weight, fasting glucose, TC, LDL cholesterol, and 
  triglycerides). Reductions in movement disorders assessed 
by the SAS and Abnormal Involuntary Movement Scale 
scores were also observed with ziprasidone but not 
  clozapine. Clozapine-intolerant and clozapine-resistant 
participants were not distinguished from one another in this 
study which may have affected the results. The investigators 
also acknowledge that the mean dosage of clozapine 
(346 mg/day) was within the therapeutic range but lower 
than may be used in clinical practice.
Nonpharmacological treatment
A thorough appraisal of the value of nonpharmacological 
treatment options is beyond the scope of this review, however 
in the context of treatment resistance it is important to Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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acknowledge the potential role of cognitive behavioral 
therapy (CBT) and electroconvulsive therapy (ECT).
Cognitive behavioral therapy
Recent studies have shown that CBT may be beneficial for 
those resistant to clozapine. Barretto et al compared CBT for 
psychosis (n = 12) to nonspecific social support also termed 
“befriending” (BF, n = 9) over 20 individualized therapy 
sessions over 3 weeks and at 6 months.96 The clozapine dose 
remained the same for all participants throughout the trial 
and the rater was blinded for the participants’ intervention. 
At 6 months modest improvements were observed in the 
BPRS total score (CBT mean = 25.00, SD 6.85 versus BF 
mean = 19.00, SD 8.38, P = 0.0092), PANSS total score 
(CBT mean = 74.11, SD 8.76 versus BF mean = 66.54 
SD 13.95, P = 0.0447), and PANSS general symptom sub-
scale (CBT mean = 38.44, SD 6.63 versus BF mean = 33.45 
SD 7.27, P = 0.0147). Participants with residual negative 
symptoms such as conceptual disorganization, emotional 
withdrawal, and blunted affect were excluded from the study. 
Although this approach is rational, since such people may 
not be able to engage in and benefit from CBT, this limits 
the generalizability of the findings; many people with TRS 
have residual negative symptoms.
Turkington et al compared CBT (n = 31) and BF (n = 28) 
over a 5-year period in individuals with schizophrenia and 
persistent positive symptoms despite adequate trials of antip-
sychotic medication.97 Improvements were observed with 
CBT in overall symptoms severity (NNT = 10.36, 95% 
CI −10.21 to −10.51) and level of negative symptoms 
(NNT = 5.22, 95% CI 5.06–5.37). While these results suggest 
that CBT may improve outcomes for participants, there was 
a significant break between the intervention which was 
completed at 9 months and follow-up at 18 months and 
5 years. Intermediate follow-up assessments and booster 
sessions may have revealed greater benefits for CBT.
electroconvulsive therapy
Matheson et al performed a systematic meta-review to deter-
mine the benefits and adverse outcomes associated with   
ECT and repetitive transcranial magnetic stimulation (rTMS)   
for people with schizophrenia.98 In contrast to ECT which   
produces global central nervous system excitation and 
generalized seizures, rTMS allows for targeted stimulation 
of superficial layers of the brain which may be effective for 
specific symptoms of schizophrenia.99 Furthermore, rTMS is 
subconvulsive and does not require an anesthetic or muscle 
relaxant. Five systematic reviews with meta-analysis were 
included in this meta-review (2 ECT, 3 rTMS) and graded in 
terms of the quality of evidence. High quality evidence sug-
gested a short-term, small effect with ECT for the improve-
ment of global symptoms in participants with or without 
concurrent antipsychotics (RR = 0.76, 95% CI 0.63–0.92).98,100 
For rTMS, high quality evidence suggests a moderate to large 
decrease in auditory hallucinations (D = 0.88, 95% CI 
0.52–1.23).98,101 No evidence was found for long-term thera-
peutic or adverse effects of either treatment.
Lévy-Rueff et al conducted a retrospective chart review 
of 19 participants with schizophrenia or schizoaffective 
disorder nonresponsive or only partially responsive to phar-
macological agents.102 In addition to antipsychotic   medication, 
participants received maintenance ECT (M-ECT) beyond 
acute episodes of psychosis. Participants received an average 
of 47 sessions of bilateral M-ECT at 1- to 8-week intervals 
for a mean period of 43 months. Improvements in mood, 
delusions, anorexia, suicidal ideation, and anxiety were 
observed but symptom scores were not reported. With 
M-ECT the mean duration of yearly hospitalizations 
decreased by 80% within this cohort from 10.5 months 
(SD 17 months) in the year preceding M-ECT to 2.1 months 
(SD 2.04 months). The mean duration of each hospitalization 
decreased by 40%, from 4.13 months (SD 4.0 months) prior 
to M-ECT to 2.53 months (SD 3.47). An improvement in 
daily functioning was also reported for most participants; 
2 participants were discharged from full-time hospitalization 
and 1 returned to employment.
Conclusion
The results of the large trials CATIE and CUtLASS chal-
lenged the widely held belief that SGAs are superior to FGAs 
in treatment-responsive schizophrenia. One concept that 
remains unchanged is clozapine’s superiority over both SGAs 
and FGAs in treatment-resistant schizophrenia; a finding 
reinforced by the second phase of each of these studies (and 
in the case of CATIE the third phase also) and the recent 
meta-analyses and RCTs presented in this review. In addition 
to people with treatment-resistant schizophrenia, studies sug-
gest that clozapine may be useful for those at high risk of 
suicide or aggression. The adverse effects of clozapine are   
significant, ranging from acute events such as   agranulocytosis 
to insidious weight gain and the onset of the metabolic 
syndrome. Many studies reported that clozapine treatment 
produced the greatest increase in BMI and/or body weight, 
closely followed by olanzapine.
The evidence supporting clozapine augmentation is weak 
and the benefits observed were moderate at best with the Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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exception of lamotrigine. In the meta-analysis by Tiihonen 
et al63 lamotrigine produced significant improvements in the 
total PANSS or BPRS score and positive and negative symp-
tom subscales. The use of the NMDA receptor antagonist 
memantine was supported by a recent RCT, which reported 
improvements in the MMSE, total BPRS, and positive and 
negative symptom subscales. Limited evidence suggests that 
NMDA agonists may produce clinical improvements in 
participants taking olanzapine or risperidone, but not clozap-
ine, while the addition of topiramate to clozapine was of little 
benefit at doses low enough to preserve cognitive function. 
Clozapine augmentation with aripiprazole resulted in weight 
loss or at least halted further weight gain without causing 
clinical deterioration or improvement.
Recent RCTs suggest that high-dose olanzapine may be an 
important alternative for people intolerant or resistant to clo-
zapine; evidence for the use of ziprasidone in these conditions 
is limited. CBT in addition to a nonclozapine antipsychotic for 
people not responding or intolerant to clozapine is supported 
by small trials. ECT (with or without concurrent antipsychotic 
medication) was found to produce small, short-term improve-
ments in global functioning, while significant improvements 
specifically in auditory hallucinations were observed with 
rTMS. However, more studies are required to determine the 
long-term and adverse effects of these treatments.
In terms of clinical practice recommendations where 
there is a lack of evidence from RCTs to guide treatment, 
clinicians should review single case reports or case series, 
which are beyond the scope of this review. When implement-
ing a treatment strategy for which there is limited evidence 
clinicians should ensure that the treatment trial is adequate 
with objective outcome measures, for example the PANSS. 
Larger trials with prospective data using clinically important 
outcomes measured by well-validated, approved instruments 
are needed to accurately compare the agents available for the 
treatment of schizophrenia. Future trials on clozapine aug-
mentation strategies should aim to distinguish between 
augmenting agents rather than comparing the results of all 
antipsychotic augmentation irrespective of mechanism of 
action.
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